Kantonsspital St.Gallen
login

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H Beumer, Edward Chu, Carmen Allegra, Yusuke Tanigawara, Gerard Milano, Robert Diasio, Tae Won Kim, Ron H Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku & Markus Joerger

abstract 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.
   
citation Beumer J H, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim T W, Mathijssen R H, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther 2018;.
   
type journal paper/review (English)
date of publishing 20-06-2018
journal title Clin Pharmacol Ther
ISSN electronic 1532-6535
PubMed 29923599
DOI 10.1002/cpt.1124